At a glance
ClinicalIndex Comparison RecordN/ACompleted· 154 enrolled
Drug / intervention
Guanfacine +2 moredrug
Likely dose
Guanfacine 0.1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects
In Brief
A clinical study evaluating Guanfacine and Placebo for Cognitive Aging. Completed, enrolled 154 participants across 1 site.
Detailed Summary
This proposal aims to determine whether low does of the alpha-2A-adrenoceptor agonist guanfacine can improve deficits in prefrontally-mediated cognitive functions in healthy elderly subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCognitive Aging
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedJul 2009
Primary CompletionAug 2012
TodayJul 2026
First PostedJul 9, 2009
Enrollment StartJun 1, 2009
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 17.0 years ago
Interventions
Guanfacinedrug
Guanfacine 0.1 mg po qhs
Guanfacinedrug
Guanfacine 0.5 mg po qhs
Placebodrug
Placebo po qhs